Prevalence of drugs as triggers of exacerbations in chronic urticaria

De



Prevalence of drugs as triggers of exacerbations in chronic urticaria
J. Sánchez Jorge1,2, A. Sánchez1,2,3, R. Cardona1,2


1. Group of Clinical and Experimental Allergy. IPS Universitaria, University of Antioquia, Medellin, Colombia.
2. Foundation for the Development of Medical and Biological Sciences (FUNDEMEB), Cartagena, Colombia.
3. Faculty of Medicine, Corporation University Rafael Nunez, Cartagena, Colombia. 
ABSTRACT 3 

Background: Many patients with chronic spontaneous urticaria (CSU) identify different drugs as triggers of their symptoms and often make restrictions without enough information.


Objective: To estimate the clinical impact of the drugs most frequently reported as suspects of CSU exacerbations by patients.

Methodology: All subjects were questioned about their clinical history of urticaria and drug reactions. Drug challenge tests were performed on each patient with the suspicious drugs. A group of healthy subjects were included as control to evaluate the prevalence of self-reported drug reactions.


Results: 245 patients with CSU and 127 healthy subjects were included. 92 (37.5%) patients and 30 (23,6%) subjects in the control group reported at least one adverse drug reaction. Non-steroidal anti-inflammatory drugs (NSAIDs) (27.7%) and Beta-lactams (9.4%) were the most common drugs reported by CSU group and the control group, respectively. Positive results of challenge tests were lower than self-reports in CSU (13%) and the control group (0.7%).

Conclusion: Self-report is usually not enough to determine a drug reaction. Drug reactions to NSAIDs and beta-lactams are higher among patients with CSU than in subjects without urticaria. Drug challenge tests should be offered early during medical evaluation to avoid unnecessary restrictions.

Texto completo: doi: 10.18176/jiaci.0287

Comentarios

Publicar un comentario

Entradas populares de este blog

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

De
ICON: Diagnosis and management of allergic conjunctivitis. Authors: Bielory L1, Delgado L2, Katelaris CH3, Leonardi A4, Rosario N5, Vichyanoud P6. Author information Abstract Ocular allergy (OA), interchangeably known as allergic conjunctivitis, is a common immunological hypersensitivity disorder affecting up to 40% of the population. Ocular allergy has been increasing in frequency, with symptoms of itching, redness, and swelling that significantly impacts an individual's quality of life (QOL). Ocular allergy is an often underdiagnosed and undertreated health problem, because only 10% of patients with OA symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary nonpharmacological remedies. The clinical course, duration, severity, and co-morbidities are varied and depend, in part, on the specific ocular tissues that are affected and on immunologic mechanism(s) involved, both local and systemic. It is frequently associat...
Leer más

Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).

De
 Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).  Fecha de actualización: viernes 20 de marzo 2020 Versión: 7 1. Introducción El 31 de diciembre de 2019 la Comisión Municipal de Salud y Sanidad de Wuhan (provincia de Hubei, China) informó sobre un agrupamiento de 27 casos de neumonía de etiología desconocida con inicio de síntomas el 8 de diciembre; los casos reportaban antecedente de exposición común a un mercado de mariscos, pescados y animales vivos en la ciudad de Wuhan. El 7 de enero de 2020, las autoridades chinas identificaron como agente causante del brote un nuevo tipo de virus de la familia Coronaviridae, que fue denominado “nuevo coronavirus”, SARS-COV-2 (1). Dado que los casos de coronavirus suelen causar síntomas respiratorios, la Organización Mundial de la Salud (OMS) ha emitido recomendaciones de protec...
Leer más

BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. Martes 14 de abril

De
BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study Authors: Jenneke Leentjens 1, Matthijs Kox 2, Robin Stokman 2, Jelle Gerretsen 2, Dimitri A Diavatopoulos 3, Reinout van Crevel 4, Guus F Rimmelzwaan 5, Peter Pickkers 2, Mihai G Netea 4 Abstract Background: Influenza-related morbidity and mortality remain high. Seasonal vaccination is the backbone of influenza management but does not always result in protective antibody titers. Nonspecific effects of BCG vaccination related to enhanced function of myeloid antigen-presenting cells have been reported. We hypothesized that BCG vaccination could also enhance immune responses to influenza vaccination. Methods: Healthy volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized fashion, followed by intramuscular injection of trivalent influenza vaccine 14 days later. Hemagglutination-inhibiting (H...
Leer más